Talk Your Book: Investing in Science Fiction

Episode Summary

Executive Summary: The episode features a conversation with Kevin Kelly, founder of Kelly Intelligence, about gene editing and the investable opportunity in CRISPR-focused public equities. The hosts explore CRISPR as a “healthcare 2.0” platform that could shift medicine from treating disease to curing it, while also discussing risks around designer babies, regulation, commercialization, and whether public-market biotech can resemble venture capital.

Main Topics: Gene editing as healthcare 2.0 (Priority: 5/5): Kelly frames CRISPR and gene editing as a step-change in medicine: instead of chronic treatment, the technology can potentially cure disease with one-time interventions. How CRISPR works and why it matters (Priority: 5/5): The discussion explains CRISPR as biological scissors that cut out bad DNA and replace it with good DNA, enabling in vivo and ex vivo treatments. Ethical and societal concerns (Priority: 4/5): The hosts and Kelly discuss fears around designer babies, selecting traits, and broader concerns about gene editing becoming too powerful or socially disruptive. Kelly Intelligence’s thematic ETF approach (Priority: 4/5): Kelly explains his strategy of concentrated, pure-play thematic ETFs designed to avoid diluted exposure and focus on companies directly tied to the theme. Investment case for CRISPR public equities (Priority: 5/5): Kelly argues that CRISPR companies are platform businesses with multiple shots on goal, cash-rich balance sheets, and clinical-trial-driven upside, making them akin to public venture capital. Commercialization, regulation, and market structure (Priority: 4/5): The conversation covers FDA dependence, partnerships with large pharma, revenue models via licensing, and the transition from rare diseases to common diseases.

Key Arguments: CRISPR is not just another biotech tool; it is a platform technology that can potentially cure diseases with one-time treatments rather than ongoing medication. Investors should think of CRISPR companies as healthcare technology platforms, not traditional single-drug biotech firms vulnerable to patent cliffs. The opportunity set is expanding because more companies are going public, more modalities exist beyond CRISPR-Cas9, and the ecosystem now includes editing, development, and sequencing companies. Clinical trial progress, not earnings, is the main value driver for these stocks because success in trials validates the platform and raises the probability of future applications. Large pharma partnerships validate the space and provide capital, while also allowing gene-editing companies to scale without bearing the entire commercialization burden. The ETF is designed to provide concentrated, pure-play exposure rather than diluted exposure to unrelated healthcare or real-estate names. Ethical concerns are real, especially around trait selection and designer babies, but Kelly says the scientific and regulatory community is already building guardrails.

Data Points: QYLD ETF assets: over 6 billion - Kelly said he launched QYLD and it has grown to more than $6 billion. Real estate ETF assets: one and a half billion plus - Kelly said his server and INDS real estate ETFs each helped build a platform exceeding $1.5 billion. Portfolio concentration: 20 to 30 names - Kelly described his thematic ETFs as generally holding 20–30 pure-play names. CRISPR ETF portfolio mix: 70% / 15% / 15% - He said XDNA is 70% CRISPR and gene editing companies, 15% development solution companies, and 15% genetic sequencing companies. CRISPR revolution timeline: 10 years - Kelly said the modern CRISPR revolution began about 10 years ago, with a key paper in June 2012. First successful in vivo CRISPR application: June 2021 - Kelly cited the first successful direct-in-body CRISPR application as a major milestone. Pfizer-Beam partnership: $1.4 billion - Kelly referenced Pfizer’s strategic partnership with Beam to apply gene-editing technology to three diseases. Enterprise value vs. market cap: enterprise value less than market cap - He argued some companies have more cash than implied by valuation because partners fund development. Typical market cap range: $500 million to $10 billion - Kelly estimated the ETF’s companies range from about $500 million to $10 billion in market cap, with a weighted average around $4–6 billion. Efficacy example: 87% efficacy rate - Kelly used a high efficacy figure to explain why regulators and committees may fast-track successful programs. Gene-edited crop adoption: first mass-adoption crop in Japan earlier this year - He noted the first gene-edited crop reached mass adoption in Japan, showing the technology is spreading beyond medicine.

Pivotal Quotes: "CRISPR and gene editing technology cures diseases." — Kevin Kelly: Kelly contrasted gene editing with traditional medicine, arguing it represents a shift from treatment to cure. "This is healthcare 2.0. It’s the next evolution of humanity and society." — Kevin Kelly: He used this phrase to summarize the long-term significance of gene editing as a platform. "We’re investing in the new healthcare and that is companies that are in the gene editing space." — Andreessen Horowitz GP (as quoted by Kevin Kelly): Kelly cited this Barron’s interview to show institutional validation of the theme.

Implications: Gene editing may become a major healthcare and investing theme, but outcomes will depend on trial success, regulation, and commercialization. For investors, the segment could offer venture-like upside in public markets, while raising ethical and policy questions that will intensify as the technology matures.